Biotechnology Technology Export Licensing Law In Russia.
1. Introduction
Biotechnology technology export licensing law in Russia concerns the legal regulation of exporting biotechnology-related products, scientific knowledge, technical documentation, biological materials, genetic technologies, laboratory equipment, microorganisms, pharmaceutical manufacturing technologies, and other sensitive biological innovations from the Russian Federation to foreign countries.
The Russian regulatory framework combines export-control legislation, licensing requirements, customs regulation, intellectual-property protection, biosecurity rules, and international non-proliferation obligations.
The principal objective is to facilitate legitimate international scientific and commercial cooperation while preventing biotechnology exports from contributing to the development of biological weapons, prohibited military applications, or other activities that threaten national security.
Technology exports may include:
Genetic engineering and genome-editing technologies.
Synthetic biology platforms and DNA synthesis systems.
Industrial biotechnology and fermentation technologies.
Vaccine and pharmaceutical manufacturing processes.
Pathogenic microorganisms and biological agents.
Laboratory equipment and specialized biological instruments.
Technical drawings, software, scientific data, and manufacturing know-how.
Technology transferred through technical assistance, licensing agreements, or digital communications.
An important distinction is that not every biotechnology export requires an export licence. The requirement depends on the nature of the item or technology, its technical characteristics, its destination, its intended end use, and applicable export-control lists.
2. Constitutional and Legislative Framework
Russia regulates biotechnology exports through several interconnected legal instruments.
A. Constitution of the Russian Federation
The Constitution establishes the general framework for federal authority, economic activity, protection of property, scientific development, and national security.
Relevant constitutional principles include:
Article 34: Freedom to use one's abilities and property for entrepreneurial and other economic activities not prohibited by law.
Article 35: Protection of private property.
Article 44: Protection of intellectual property and freedom of scientific and creative activity.
Article 71: Federal jurisdiction over foreign policy, international relations, defence, and foreign economic regulation.
These provisions provide the constitutional foundation for regulating technology exports while protecting lawful commercial and scientific activity.
B. Federal Law No. 183-FZ of 18 July 1999
Federal Law on Export Control
This is the central legislation governing exports of controlled technologies and goods.
Its principal objectives include:
Preventing the proliferation of weapons of mass destruction.
Controlling exports of dual-use goods and technologies.
Protecting national security.
Regulating foreign trade involving sensitive technologies.
Preventing unauthorized transfers of controlled technical information.
Biotechnology is particularly relevant where biological materials, equipment, technical information, or production processes could have both civilian and military applications.
The law provides the basis for identifying controlled items, obtaining permissions, conducting expert assessments, and imposing responsibility for export-control violations.
C. Federal Law No. 164-FZ of 8 December 2003
This law concerns the fundamentals of state regulation of foreign trade activity.
It establishes the broader framework for international trade, including:
Export and import regulation.
State licensing mechanisms.
Foreign trade restrictions.
Government supervision.
International commercial transactions.
Where biotechnology products are subject to special restrictions, the export-control framework operates alongside general foreign-trade legislation.
D. Federal Law No. 61-FZ of 12 April 2010
Law on Circulation of Medicines
This legislation is relevant when biotechnology exports involve:
Vaccines.
Recombinant biological medicines.
Monoclonal antibodies.
Biosimilars.
Gene-therapy products.
Other biological medicinal products.
Medicinal products must comply with applicable registration, quality, safety, manufacturing, and circulation requirements.
An export-control authorisation does not replace pharmaceutical regulatory approvals.
E. Federal Law No. 86-FZ of 5 July 1996
Law on State Regulation in the Field of Genetic Engineering
This law establishes legal requirements concerning genetic-engineering activities.
Its relevance includes:
Genetically modified organisms.
Genetic-engineering research.
Safety assessment.
Handling and use of genetically modified biological materials.
State supervision of relevant activities.
The law must be considered together with applicable export-control and customs requirements.
3. Government Resolution No. 1287 of 16 July 2022
Central biotechnology export-control regulation
One of the most important instruments is Government Resolution No. 1287 of 16 July 2022, titled On Approval of the List of Microorganisms, Toxins, Equipment and Technologies Subject to Export Control.
The resolution establishes seven principal categories:
| Section | Regulated subject |
|---|---|
| 1 | Microorganisms pathogenic to humans and toxins |
| 2 | Microorganisms pathogenic to animals |
| 3 | Microorganisms pathogenic to plants |
| 4 | Genetically modified microorganisms and genetic elements |
| 5 | Equipment |
| 6 | Technologies |
| 7 | Software |
The list was amended by Government Resolution No. 2138 of 13 December 2023, with the amendments taking effect in March 2024.
Consultant Plus+1
Legal significance
The resolution is particularly important because it covers not only physical biological materials but also technology and software.
For example, a Russian biotechnology company exporting a controlled genetic-engineering technology may need authorisation even when it does not physically export a microorganism.
The list also distinguishes between controlled technology and information that is outside export control.
Important exemptions include:
Publicly available information.
Fundamental scientific research.
Information necessary for preparing a patent application.
Certain publicly available software.
These exemptions are not a blanket exemption for all academic or commercial biotechnology research. The actual nature of the information and the applicable list entry must be examined.
sudact.ru+1
4. Types of Biotechnology Technology Subject to Export Licensing
A. Genetic engineering technology
Genetic engineering is an important area of Russian export control.
Controlled technology may include specialized technical information concerning the development, production, or use of listed genetically modified microorganisms and genetic elements.
Potentially regulated transactions include:
Transfers of controlled genetic-engineering protocols.
Licensing of restricted biological production processes.
Technical assistance concerning controlled organisms.
Transfers of specialized manufacturing documentation.
However, an ordinary genetic-testing service or the transfer of routine scientific information does not automatically constitute a controlled export.
B. Synthetic biology technology
Synthetic biology combines biological engineering, genetic modification, computational design, and biological manufacturing.
Export-control assessment may become necessary when a technology falls within the descriptions in the controlled list.
Relevant commercial activities may involve:
Synthetic biological production platforms.
Specialized genetic constructs.
Controlled biological production methods.
Technical information relating to listed organisms.
Specialized software associated with controlled biological technology.
C. Pharmaceutical biotechnology
Pharmaceutical biotechnology exports may involve:
Recombinant protein manufacturing.
Vaccine-production technology.
Monoclonal antibody manufacturing.
Cell-culture technology.
Biological fermentation systems.
Specialized purification equipment.
The exporter must distinguish between pharmaceutical regulatory compliance and export-control compliance.
A product's pharmaceutical registration does not automatically establish that its export is exempt from export-control requirements.
D. Laboratory equipment and manufacturing technology
Specialized laboratory equipment may be controlled where it satisfies the technical descriptions in the relevant export-control list.
Technology supplied alongside equipment may also be regulated.
Resolution No. 1287 provides that authorisation to export controlled equipment to a particular end user also covers technology necessary for that user's installation, operation, maintenance, or repair of the equipment, within the limits stated in the resolution.
sudact.ru
5. Export Licensing Procedure in Russia
The export licensing process generally involves several stages.
Identification of the technology
The exporter identifies the biological material, equipment, technical information, software, or intellectual-property rights involved in the transaction.
Classification under the control lists
The exporter compares the technical characteristics of the proposed export with the applicable controlled-item lists, particularly Resolution No. 1287.
End-user and end-use assessment
The exporter examines the foreign recipient, destination, proposed use, contractual restrictions, and possible onward transfers.
Preparation of supporting documentation
Documentation may include the export contract, technical description, classification assessment, end-user information, and details of the proposed transaction.
Application for authorisation
Where required, the exporter applies to the competent Russian authority or obtains the relevant permission through the applicable export-control procedure.
Customs declaration
The exporter provides the required export-control documents and customs declarations.
Post-export compliance
The exporter maintains transaction records, monitors contractual end-use restrictions, and addresses any subsequent changes in the intended use or recipient.
Role of FSTEC Russia
The Federal Service for Technical and Export Control (FSTEC Russia) plays a central role in administering Russia's export-control system.
Its functions include:
Export-control supervision.
Identification and classification procedures.
Administration of relevant authorisations.
Monitoring compliance with export-control requirements.
Coordination with other competent government authorities.
The exporter remains responsible for correctly identifying controlled goods and technologies. Article 24 of Federal Law No. 183-FZ is particularly important in this regard.
sudact.ru+1
6. Regulation of Intangible Technology Transfers
A particularly significant feature of Russian export-control legislation is that regulation is not limited to physical exports.
A biotechnology company may transfer technology through:
Email attachments.
Online scientific databases.
Remote technical consultations.
International research collaborations.
Software access.
Cloud-based technical documentation.
Training and technical assistance.
Licensing of intellectual-property rights.
Under the export-control framework, technology means specialized information necessary for the development, production, or use of controlled products.
Technical assistance can include training, practical instruction, professional consultation, and the transfer of technical experience.
Consequently, an international biotechnology collaboration can raise export-control issues even where no biological sample physically crosses the Russian border.
sudact.ru+1
7. End-User and End-Use Restrictions
Russian export-control law places considerable importance on the identity of the foreign recipient and the intended purpose of the transaction.
A biotechnology exporter should examine:
Whether the foreign recipient is legally identifiable.
Whether the recipient is a research institution, commercial company, or government organisation.
Whether the technology will be used for legitimate civilian purposes.
Whether the recipient intends to transfer the technology to another organisation.
Whether the transaction presents biological-weapons proliferation risks.
Whether the contractual end-use conditions are consistent with the export authorisation.
A transaction that initially appears to involve civilian research may require additional scrutiny where the actual end use is uncertain.
8. Relationship With Customs and Pharmaceutical Regulation
Biotechnology export licensing does not operate independently of other regulatory systems.
| Regulatory framework | Main function |
|---|---|
| Federal Law No. 183-FZ | Export control |
| Government Resolution No. 1287 | Biological export-control list |
| Federal Law No. 164-FZ | Foreign trade regulation |
| Federal Law No. 61-FZ | Medicinal-product regulation |
| Federal Law No. 86-FZ | Genetic-engineering regulation |
| EAEU Customs Code | Customs procedures and declarations |
A company may therefore need to satisfy more than one legal requirement.
For instance, exporting a biological medicinal product could require pharmaceutical documentation, customs compliance, and a separate export-control authorisation if the product or associated technology falls within the relevant controlled categories.
9. Important Judicial Decisions and Case Laws
Russian biotechnology export-control law has a relatively limited body of publicly accessible decisions specifically addressing biotechnology technology exports. However, several important Russian court decisions concerning biological materials, controlled technology, and export-control compliance establish relevant legal principles.
Case 1: Arbitration Case No. A56-6600/2022 — Export of Controlled Goods Without Authorisation
Important export-control precedent
Decision dated: 20 June 2022.
Court: Russian commercial arbitration court.
Legal provisions considered:
Federal Law No. 183-FZ.
Article 24 — Identification of controlled goods and technologies.
Article 30 — Violations of export-control requirements.
Article 14.20 of the Code of Administrative Offences.
Facts and legal issues:
The dispute concerned the export of goods that were considered subject to export control.
The company argued that expert documentation supported its position that an export licence was unnecessary.
However, the court considered the technical characteristics of the goods and the expert assessments. It found that the submitted specialist opinion did not adequately address characteristics relevant to the applicable controlled-item list.
The court upheld the finding that the company had violated export-control requirements by undertaking an international transaction without the necessary authorisation.
Legal principle:
An exporter cannot avoid export-control responsibility merely by relying on an inadequately reasoned technical assessment.
Relevance to biotechnology:
A biotechnology exporter must establish the technical classification of biological equipment, genetic-engineering systems, and specialised production technologies. An unsupported statement that a product is intended for civilian research may not be sufficient.
sudact.ru
Case 2: Arbitration Case No. A56-57752/2023 — Export of Human Biological Materials
Decision dated: 6 December 2023.
Legal framework:
Federal Law No. 183-FZ.
Article 19 — Licensing of controlled foreign-trade operations.
Government Resolution No. 517 of 15 August 2005.
Export-control requirements concerning biological materials.
Facts:
The dispute concerned the export of human biological materials to a foreign company.
The Russian company challenged the need for additional export-control authorisation and relied on the claimed research-related purpose of the transaction.
The regulatory authorities raised concerns about the lack of sufficient information concerning the ultimate purpose of the samples and the possibility of their transfer to third parties.
The court examined the circumstances surrounding the transaction, the contractual arrangements, and the relevant regulatory requirements.
Legal principle:
The declared civilian purpose of exporting biological materials does not necessarily eliminate the requirement for export-control assessment.
Where the actual intended use and the foreign recipient's subsequent handling of the samples are unclear, additional regulatory authorisation may be required.
Relevance to biotechnology:
This decision is particularly important for:
Genetic research companies.
Biobanks.
Human tissue laboratories.
Genomic research organisations.
International clinical research providers.
sudact.ru
Case 3: Arbitration Case No. A56-36285/2023 — International Transfer of Human Biological Samples
Decision dated: 18 March 2024.
Legal framework:
Federal Law No. 183-FZ.
Government Resolution No. 517 of 15 August 2005.
Customs and export-control requirements.
Article 16.3 of the Code of Administrative Offences.
Facts:
A Russian company arranged the delivery of human biological samples to foreign organisations under contractual arrangements.
The company maintained that the samples were being transferred for laboratory examinations and medical or diagnostic purposes.
However, the authorities identified problems with the supporting documentation, including insufficient evidence establishing the actual purpose of the biological samples and the conditions governing their subsequent use.
The export-control authority considered that the transaction required the relevant permission because the intended use had not been adequately established.
Court's reasoning:
The dispute illustrates the importance of distinguishing between:
Medical regulatory permission.
Customs authorisation.
Export-control permission.
Compliance with one regulatory requirement does not automatically satisfy the others.
Legal principle:
A company must independently establish compliance with applicable export-control restrictions. Medical or diagnostic authorisation alone does not necessarily permit the international transfer of biological materials.
Relevance to biotechnology:
The decision has implications for international genomic testing, biological sample transportation, cell research, and cross-border laboratory services.
sudact.ru
Case 4: Arbitration Case No. A56-36287/2023 — Failure to Obtain Export-Control Permission
Decision dated: 7 March 2024.
Legal provisions:
Federal Law No. 183-FZ.
Government Resolution No. 517 of 15 August 2005.
Article 16.3 of the Code of Administrative Offences.
Facts:
The company exported human biological materials without obtaining the export-control permission considered necessary by the authorities.
The company argued that the relevant medical regulatory documentation was sufficient and that customs clearance had been granted.
The court rejected the argument that medical regulatory documentation replaced export-control authorisation.
It also considered the company's failure to demonstrate that it had taken all necessary measures to comply with the applicable legal requirements.
Legal principle:
Customs clearance does not legalise an export transaction that otherwise violates mandatory export-control restrictions.
Relevance to biotechnology:
Biotechnology businesses must independently verify export-control compliance before shipping biological materials, even when they possess other regulatory approvals.
sudact.ru
Case 5: First Cassation Court of General Jurisdiction — Case No. 7У-9401/2025
Decision dated: 27 January 2026.
Subject: Unlawful transfer of scientific and technical information to a foreign organisation.
Legal framework: Article 189 of the Russian Criminal Code, as well as the applicable export-control legislation.
Facts:
The proceedings concerned the transfer of scientific and technical information to a representative of a foreign organisation. The information was considered capable of being used in the development of weapons of mass destruction and subject to export control.
The accused challenged the conviction, arguing, among other things, that the information was not secret, had been obtained through international scientific cooperation, and was not intended for military use.
The defence also raised issues concerning the interpretation of Article 189 following legislative amendments.
Legal significance:
The case illustrates the importance of distinguishing between the confidentiality of information and its status under export-control law.
Information need not necessarily be classified as a state secret to attract export-control restrictions.
Relevance to biotechnology:
The same legal distinction is important when assessing international transfers of controlled genetic-engineering protocols, biological production methods, specialised technical documentation, and other controlled scientific information.
This case is not a biotechnology-specific decision, and its application to biotechnology must be made by analogy with the relevant export-control provisions.
ГАРАНТ
10. Administrative and Criminal Liability
Violations of biotechnology export-control requirements can result in administrative or criminal proceedings, depending on the conduct and applicable statutory elements.
A. Administrative liability
Article 14.20 of the Russian Code of Administrative Offences
This provision addresses violations of legislation concerning export control.
Potential violations include:
Exporting controlled biotechnology equipment without the required authorisation.
Unauthorised transfer of controlled technical information.
Breaching applicable export-control conditions.
Undertaking controlled foreign-trade operations contrary to licensing requirements.
Case No. A56-6600/2022 illustrates the application of this provision.
Article 16.3 of the Russian Code of Administrative Offences
This provision concerns non-compliance with prohibitions and restrictions applicable to the movement of goods across the customs border.
It is particularly relevant where biological materials are exported without the required permissions.
Cases Nos. A56-36285/2023 and A56-36287/2023 illustrate this issue.
B. Criminal liability
Article 189 of the Russian Criminal Code
This provision concerns unlawful export from or transfer to Russia, as well as certain other unlawful activities involving controlled goods, technologies, scientific and technical information, and services, subject to its statutory elements.
Potentially relevant conduct includes unlawful transactions involving controlled biotechnology technologies.
Article 226.1 of the Russian Criminal Code
This provision addresses specified forms of smuggling, including certain controlled goods and strategic resources.
Its application depends on the nature of the goods, the applicable statutory provisions, and the circumstances of the transaction.
Important distinction: Not every failure to obtain an export licence constitutes a criminal offence. Criminal liability requires proof of the elements of the relevant criminal offence, whereas administrative liability may apply to conduct that does not meet the criminal threshold.
11. Intellectual Property Rights and Biotechnology Export Licensing
Export-control regulation must also be considered alongside Russian intellectual-property legislation.
The principal legislation includes:
Part IV of the Russian Civil Code.
Patent protection provisions.
Trade-secret protection.
Software copyright.
Technology licensing agreements.
Confidentiality and know-how arrangements.
Biotechnology companies frequently commercialise technologies through licensing agreements rather than physical exports.
For example, a Russian company may grant a foreign pharmaceutical manufacturer the right to use a particular biological manufacturing process.
If the licensed technology is controlled, the transfer of intellectual-property rights or associated technical information may require export-control authorisation.
An intellectual-property licence is therefore not automatically an export-control licence.
12. International Legal Framework
Russian biotechnology export regulation also operates within the framework of international non-proliferation obligations.
A. Biological Weapons Convention 1972
The Biological Weapons Convention prohibits the development, production, stockpiling, acquisition, and retention of biological and toxin weapons, subject to its provisions.
Article III is particularly relevant to international transfers.
It requires States Parties not to transfer biological weapons, their agents or toxins, weapons, equipment, or means of delivery specified in the Convention, and not to assist or encourage their acquisition.
This international framework provides an important rationale for national biotechnology export controls.
B. United Nations Security Council Resolution 1540
Resolution 1540 (2004) requires states to establish appropriate domestic controls to prevent non-state actors from acquiring weapons of mass destruction and related materials.
This includes relevant biological materials and associated technologies.
C. Eurasian Economic Union
Russia's membership in the Eurasian Economic Union creates an additional regulatory dimension.
The EAEU customs framework regulates the movement of goods across the customs territory, while applicable non-tariff measures and Russian export-control requirements must also be observed.
Practical consequence: An exporter must distinguish between customs classification, pharmaceutical regulation, biological safety requirements, and export-control classification.
13. Major Compliance Challenges in Russian Biotechnology Exports
Several legal difficulties arise when Russian biotechnology companies conduct international transactions.
| Compliance issue | Legal difficulty |
|---|---|
| Genetic engineering | Determining whether technology falls within controlled lists |
| Synthetic biology | Assessing dual-use potential |
| Biological samples | Establishing legitimate end use |
| Vaccine technology | Separating pharmaceutical approval from export authorisation |
| Digital technology transfer | Identifying controlled intangible transfers |
| International research | Distinguishing fundamental research from controlled technical development |
| Intellectual property | Reconciling licensing rights with export restrictions |
| Foreign subsidiaries | Assessing onward transfers and end users |
| Customs declarations | Ensuring accurate classification and supporting documentation |
Particularly important legal challenges
1. Scientific freedom versus national security
Russia must balance scientific cooperation and commercial biotechnology development against its export-control and non-proliferation obligations.
2. Dual-use biotechnology
The same technology may have legitimate medical applications and potentially dangerous applications. Consequently, technical classification and end-use assessment are important.
3. Cross-border digital transfers
Traditional customs procedures are designed primarily around physical goods. Modern biotechnology increasingly involves cloud-based research, digital genetic information, software, and remote technical assistance.
4. International research agreements
Universities and pharmaceutical companies must ensure that research collaboration agreements do not inadvertently authorise transfers prohibited by export-control legislation.
14. Practical Compliance Example
Consider a Russian biotechnology company intending to license a specialised genetic-engineering manufacturing process to a foreign pharmaceutical company.
The transaction involves:
A technology licensing agreement.
Transfer of technical manufacturing documentation.
Remote training of foreign scientists.
Access to specialised biotechnology software.
Technical support after the transfer.
The Russian company should determine:
Whether the manufacturing technology appears in Resolution No. 1287.
Whether the associated software is controlled.
Whether technical assistance constitutes a controlled transfer.
Whether the foreign recipient and intended end use are acceptable.
Whether an export licence or other permission is necessary.
Whether any separate pharmaceutical or intellectual-property requirements apply.
If the technology is controlled, the company must obtain the appropriate authorisation before undertaking the regulated transaction.
15. Conclusion
Biotechnology Technology Export Licensing Law in Russia is an important component of the country's national security, foreign trade, scientific research, and biological non-proliferation framework.
Federal Law No. 183-FZ provides the general legal foundation, while Government Resolution No. 1287 establishes specific controls over microorganisms, toxins, equipment, technologies, and software.
The judicial decisions discussed above demonstrate several important principles:
Exporters have an independent responsibility to identify controlled goods and technologies.
Civilian scientific purposes do not automatically remove export-control obligations.
Pharmaceutical or medical approval does not replace export-control authorisation.
Intangible scientific and technical information may fall within export-control restrictions.
Administrative and criminal liability depend on the applicable statutory requirements and the facts of each transaction.
Ultimately, Russia's biotechnology export licensing system seeks to regulate international access to sensitive biological technologies while permitting lawful scientific and commercial cooperation.
16. Important Legal Sources and Further Reading
| Legal source | Subject |
|---|---|
| Federal Law No. 183-FZ (1999) | Export control |
| Federal Law No. 164-FZ (2003) | Foreign trade |
| Federal Law No. 86-FZ (1996) | Genetic engineering |
| Federal Law No. 61-FZ (2010) | Medicinal products |
| Government Resolution No. 1287 (2022) | Controlled biological materials and technologies |
| Government Resolution No. 517 (2005) | Export-control procedures for biological materials |
| Russian Criminal Code, Article 189 | Unlawful transactions involving controlled goods and technologies |
| Russian Code of Administrative Offences, Articles 14.20 and 16.3 | Administrative violations |
| Biological Weapons Convention (1972) | International biological weapons prohibition |
Useful legal references:
Federal Law No. 183-FZ — Export Control
Government Resolution No. 1287 — Controlled microorganisms, toxins, equipment and technologies
Arbitration Case A56-6600/2022
Arbitration Case A56-36285/2023
Arbitration Case A56-36287/2023
First Cassation Court — Case 7У-9401/2025
Academic research note: The cited arbitration decisions are fact-specific judicial decisions, not necessarily binding precedents for every Russian court. The 2026 cassation decision concerns controlled scientific information in a non-biotechnology context. The legislation and its amendments should be checked against the official Russian legal publication system before relying on this analysis in an actual export transaction.

comments